More specifically, only 15% of patients with metastatic head and neck squamous cell carcinoma (HNSCC) treated with anti–PD-1 therapy have shown a response (4), and very few responses were observed in patients with microsatellite stable colorectal cancer (CRC) (1). Here, PDCD1 is linked to head and neck squamous cell carcinoma.